Although telmisartan and candesartan, both AT1-receptor blockers, are well known to have an effect of cardiac protection, just telmisartan has a unique property that partially
Losartan was the first ARB to be approved for clinical use
Terminal half-life is a major difference between ARBs, 11 being largest (≈24 hours) for telmisartan
Olmesartan medoxomil is a new ARB that was discovered during a systematic survey of the AT 1 binding actions of substituted imidazole‐5‐carboxylic
Candesartan has an average rating of 5
1
73 m 2 for enalapril (95% CI of the treatment difference −9
41% of reviewers reported a positive effect, while 35% reported a negative
Telmisartan is a member of a family of drugs called angiotensin receptor blockers (), which includes losartan (), valsartan (), irbesartan (), and candesartan ()
Telmisartan oral tablet is available as both a generic and brand-name drug
Paired t-test and a propensity score-weighted t-test were used to compare the differences in means between baseline and during the exposure period, and between olmesartan users and candesartan users
First for BW, at the end of 1st week, there were no significant differences detected between the mean BW of control, HFD, telmisartan and candesartan groups
com
37% of reviewers reported a positive effect, while 37% reported a negative
com
40% of reviewers reported a positive effect, while 35% reported a negative effect
5 or 25mg hydrochlorothiazide
The most common side effects of losartan are dizziness, nasal congestion, upper respiratory tract infections, and back pain